On February 13, 2026, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recommended the withdrawal of all levamisole-containing medicines from the European Union market. The trigger was not a minor safety update. It was a rare but potentially devastating neurological condition — leukoencephalopathy, a disorder affecting the brain’s white matter. After reviewing…
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
